FDA Clearance Tracker · P160045-S027
Oncomine Dx Target Test
Last checked: Nov 20, 2026Latest source record: Dec 1, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Dec 1, 2021
Approved
Time to decision
282 days
Received Feb 22, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160045-S027
- Device name
- Oncomine Dx Target Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Carlsbad, CA
- Received
- Feb 22, 2021
- Decided
- Dec 1, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160045
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from treatment with RYBREVANT (amivantamab-vmjw).
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.